Evaluation of immunostimulatory effects of viracomb (Rx) in rabbits

Authors

  • A. Y. Tijani Author
  • O. E. Ojo Author
  • D. K. Oladepo Author
  • O. A. Salawu Author
  • S. B. Mohammed Author
  • A. U. Osunkwo Author
  • K. S. Izebe Author
  • Y. Yaaba Author

Keywords:

Viracomb, cyclophosphamide, immuno-suppressed, rabbits,, immunostimulatory.

Abstract

Viracomb is a herbal based preparation used in management of conditions associated with immuno
supression. The present study was undertaken to evaluate the immunostimulatory effect of Viracomb in 
rabbits. Acute toxicity study was carried out in rabbits using acute toxic class method. In the 
immunostimulatory study, healthy adult rabbits were randomized into five groups of five rabbits per group. 
Group I rabbits served as the positive control and received 10 ml normal saline/kg while rabbits in groups II, 
III, IV and V received 50 mg cyclophosphamide/kg body weight on days 0, 2 and 4 and thereafter, rabbits in 
groups II, III and IV were given daily doses of 75, 150 and 300 mg Viracomb/kg body weight for 28-days while 
group V served as the negative control. The effect of viracomb on feed and water intake, body weight 
changes, CD4+ count, haematological and biochemical parameters were evaluated. The oral median lethal 
dose was estimated to be greater than 5000 mg extract/kg body weight. Viracomb exerted significant 
decrease in feed intake at 75 mg/kg while slight increase in feed intake was observed at 150 and 300 mg /kg 
body weight. Significant (p < 0.05) decrease in water intake was observed at all dose levels used for the 
study. There was no remarkable change in body weight of rabbits at all doses used for the study. There was 
significant (p < 0.05) increase in CD4+ counts of rabbits given 150 mg / body weight kg while unremarkable 
changes were observed in CD4+ counts of rabbits given 75 and 300 mg/kg body weight respectively at the 
end of the 28-days study. Significant dose dependent increase in haematological profiles was observed while 
biochemical parameters remained normal. These findings indicate that viracomb is safe acutely and possess 
immunostimulatory activity and thus, provide evidence for its acclaimed effect in the management of 
immuno-suppressed related disorders. 

Downloads

Published

2017-12-06

How to Cite

Evaluation of immunostimulatory effects of viracomb (Rx) in rabbits . (2017). African Journal of AIDS and HIV Research , 6(1), 1-7. https://kevinpage.org/index.php/AJAHR/article/view/197

Similar Articles

1-10 of 17

You may also start an advanced similarity search for this article.